Stockscreener 앱 받기
22.03
6.41%
-1.51
시간 외 거래:
22.17
0.14
+0.64%
전일 마감가:
$23.54
열려 있는:
$23.63
하루 거래량:
1.55M
Relative Volume:
1.79
시가총액:
$1.31B
수익:
-
순이익/손실:
$-131.11M
주가수익비율:
-10.13
EPS:
-2.1745
순현금흐름:
$-102.47M
1주 성능:
-23.11%
1개월 성능:
-12.51%
6개월 성능:
-39.71%
1년 성능:
+76.66%
1일 변동 폭
$21.86
$23.96
1주일 범위
$18.66
$29.49
52주 변동 폭
$11.82
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
명칭
Tyra Biosciences Inc
전화
(619) 728-4760
주소
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
22.03 | 1.31B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Guggenheim | Buy |
| 2026-04-06 | 개시 | Canaccord Genuity | Buy |
| 2026-02-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-02-10 | 개시 | William Blair | Outperform |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-21 | 재개 | Piper Sandler | Overweight |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-10-18 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-08-15 | 개시 | Piper Sandler | Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-30 | 개시 | Wedbush | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-06-23 | 개시 | H.C. Wainwright | Buy |
| 2022-03-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-10-11 | 개시 | BofA Securities | Buy |
| 2021-10-11 | 개시 | Cowen | Outperform |
| 2021-10-11 | 개시 | Jefferies | Buy |
모두보기
Tyra Biosciences Inc 주식(TYRA)의 최신 뉴스
Tyra Biosciences (TYRA) director adds shares in open-market buy - Stock Titan
Tyra Biosciences Inc. (TYRA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.TYRA - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $30 to $59 - Moomoo
Dabogratinib Shows Early Activity in FGFR3-Altered Low-Grade NMIBC - CancerNetwork
Cantor Fitzgerald reiterates Tyra Biosciences stock rating after trial data - Investing.com
Cantor Fitzgerald reiterates Tyra Biosciences stock rating after trial data By Investing.com - Investing.com Canada
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBCSlideshow (NASDAQ:TYRA) 2026-09-10 - Seeking Alpha
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $30 - moomoo.com
Tyra Biosciences at 12th Annual Cantor Fitzgerald Global Healthcare Conference: oral drug push - Investing.com Canada
Balversa reversa? Tyra’s bladder cancer drug hits in phase II - BioWorld News
Tyra disappoints investors with bladder cancer data - BioPharma Dive
Why This Biotech Stock Just Plummeted To A 10-Month Low - Investor's Business Daily
TYRA: Oral FGFR3 inhibitor shows robust efficacy and safety, advancing to phase III for MIBC - TradingView
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines (TYRA) - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why Is Tyra Biosciences Stock Sinking Wednesday? - Benzinga
Tyra Biosciences reports 79% response rate for bladder cancer drug dabogratinib - Minichart
Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short - Blockonomi
TYRA: Oral dabogratinib at 60 mg shows strong efficacy and safety, advancing to phase III in NMIBC - TradingView
Tyra reports 79% response rate in Phase 2 cancer trial - grafa.com
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress - Barron's
Tyra Biosciences stock tumbles 30% on phase 2 trial results By Investing.com - Investing.com Australia
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data - Yahoo Finance
Why is Tyra Biosciences stock plunging today? - Investing.com
Tyra Biosciences stock tumbles 30% on phase 2 trial results - investing.com
Tyra drops after mid-stage trial data for lead asset in bladder cancer - TradingView
Tyra Bioscience Reports Promising Phase 2 Dabogratinib Data - TipRanks
Tyra Biosciences reports positive Phase 2 SURF302 results, 60 mg QD chosen for registrational adjuvant plan - TradingView
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib - PR Newswire
We're Hopeful That Tyra Biosciences (NASDAQ:TYRA) Will Use Its Cash Wisely - moomoo.com
Tyra Biosciences to present at Cantor Global He... - Pluang
Tyra Biosciences sets virtual chat, investor meetings Sept. 9 - Stock Titan
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $39 to $56 - Moomoo
Piper Sandler reiterates Tyra Biosciences stock rating ahead of data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy - Investing.com
Piper Sandler Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $56 - Moomoo
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $39 - Moomoo
JonesTrading Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Tyra Biosciences downgraded to Hold ahead of ke... - Pluang
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts - Seeking Alpha
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout - Asianet Newsable
Tyra Bio rises on upcoming mid-stage trial data (TYRA:NASDAQ) - Seeking Alpha
Initial results for an oral bladder cancer drug will be discussed Sept. 9 - Stock Titan
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing - Stock Traders Daily
Tyra Biosciences draws industry focus with IR NMIBC research at IBCG26 retreat - Traders Union
Tyra Biosciences (TYRA): Can Dabogratinib Redefine FGFR3-Driven Bladder Cancer? - RTTNews
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Tyra Biosciences Inc (TYRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
1.67%
자본화:
|
볼륨(24시간):